| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
585,690,000 |
| Market
Cap: |
178.65(B) |
| Last
Volume: |
1,924,998 |
Avg
Vol: |
2,723,980 |
| 52
Week Range: |
$217.36 - $324.56 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
NASDAQ-100 |
| |
S&P 100 |
|
S&P 500 |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 499 |
| Guru Rank Value : 3 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Amgen is a biotechnology company that focuses on discovering, developing, manufacturing and delivering human therapeutics. Co.'s principal products are Enbrel® (etanercept), Prolia® (denosumab), Otezla® (apremilast), XGEVA® (denosumab), Neulasta® (pegfilgrastim), Aranesp® (darbepoetin alfa), Repatha® (evolocumab), KYPROLIS® (carfilzomib) and Nplate® (romiplostim). Co. also markets a number of other products, including among other, MVASI® (bevacizumab-awwb), Vectibix® (panitumumab), KANJINTI® (trastuzumab-anns), EVENITY® (romosozumab-aqqg), EPOGEN® (epoetin alfa), BLINCYTO® (blinatumomab), AMGEVITA™ (adalimumab), Aimovig® (erenumab-aooe), Parsabiv® (etelcalcetide) and NEUPOGEN® (filgrastim).
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
2,117 |
2,117 |
23,771 |
31,503 |
| Total Sell Value |
$662,802 |
$662,802 |
$6,471,520 |
$8,438,219 |
| Total People Sold |
1 |
1 |
3 |
6 |
| Total Sell Transactions |
1 |
1 |
4 |
8 |
| End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Jacks Tyler |
Director |
• • – |
2018-12-06 |
4 |
OE |
$82.60 |
$1,652,000 |
D/D |
20,000 |
28,979 |
|
- |
|
| Piacquad David |
SVP, Business Development |
• • – |
2018-11-30 |
4 |
D |
$202.37 |
$831,538 |
D/D |
(4,109) |
41,019 |
|
- |
|
| Piacquad David |
SVP, Business Development |
• • – |
2018-11-30 |
4 |
OE |
$54.69 |
$355,485 |
D/D |
6,500 |
45,128 |
|
- |
|
| Patton Cynthia M |
SVP & CCO |
• • – |
2018-11-29 |
4 |
S |
$202.88 |
$360,520 |
D/D |
(1,777) |
21,313 |
|
- |
|
| Patton Cynthia M |
SVP & CCO |
• • – |
2018-11-29 |
4 |
OE |
$54.69 |
$97,184 |
D/D |
1,777 |
23,090 |
|
- |
|
| Holley Charles M |
Director |
• • – |
2018-11-05 |
4 |
A |
$0.00 |
$0 |
D/D |
93 |
1,427 |
|
- |
|
| Gordon Murdo |
EVP Global Commercial Ops |
• • – |
2018-11-02 |
4 |
A |
$0.00 |
$0 |
D/D |
34,213 |
34,213 |
|
- |
|
| Reese David M |
EVP, Research and Development |
• • – |
2018-11-02 |
4 |
A |
$0.00 |
$0 |
D/D |
12,830 |
30,618 |
|
- |
|
| Kullman Ellen Jamison |
Director |
• • – |
2018-11-02 |
4 |
A |
$0.00 |
$0 |
D/D |
149 |
3,312 |
|
- |
|
| Henderson Rebecca M |
Director |
• • – |
2018-08-10 |
4 |
D |
$193.97 |
$189,509 |
D/D |
(977) |
15,220 |
|
- |
|
| Henderson Rebecca M |
Director |
• • – |
2018-08-10 |
4 |
OE |
$63.11 |
$189,330 |
D/D |
3,000 |
16,197 |
|
- |
|
| Graham Jonathan P |
SVP, Gen. Counsel & Secy. |
• • – |
2018-08-06 |
4 |
D |
$197.99 |
$1,303,962 |
D/D |
(6,586) |
41,256 |
|
- |
|
| Santos Esteban |
EVP, Operations |
• • – |
2018-08-01 |
4 |
D |
$196.55 |
$389,562 |
D/D |
(1,982) |
34,654 |
|
- |
|
| Meline David W |
EVP & CFO |
• • – |
2018-08-01 |
4 |
D |
$196.55 |
$1,450,932 |
D/D |
(7,382) |
52,202 |
|
- |
|
| Druker Brian |
Director |
• • – |
2018-07-31 |
4 |
A |
$0.00 |
$0 |
D/D |
678 |
678 |
|
- |
|
| Holley Charles M |
Director |
• • – |
2018-07-31 |
4 |
A |
$0.00 |
$0 |
D/D |
89 |
2,585 |
|
- |
|
| Kullman Ellen Jamison |
Director |
• • – |
2018-07-31 |
4 |
A |
$0.00 |
$0 |
D/D |
152 |
3,144 |
|
- |
|
| Harper Sean E |
EVP, Research & Development |
• • – |
2018-07-16 |
4 |
AS |
$195.71 |
$298,458 |
D/D |
(1,525) |
56,082 |
|
- |
|
| Harper Sean E |
EVP, Research & Development |
• • – |
2018-06-12 |
4 |
AS |
$184.27 |
$281,012 |
D/D |
(1,525) |
57,510 |
|
- |
|
| Harper Sean E |
EVP, Research & Development |
• • – |
2018-05-14 |
4 |
AS |
$174.10 |
$265,503 |
D/D |
(1,525) |
59,035 |
|
- |
|
| Piacquad David |
SVP, Business Development |
• • – |
2018-05-11 |
4 |
D |
$170.77 |
$1,683,792 |
D/D |
(9,860) |
41,706 |
|
- |
|
| Piacquad David |
SVP, Business Development |
• • – |
2018-05-11 |
4 |
OE |
$54.71 |
$820,650 |
D/D |
15,000 |
51,566 |
|
- |
|
| Patton Cynthia M |
SVP & CCO |
• • – |
2018-05-03 |
4 |
D |
$169.43 |
$28,634 |
D/D |
(169) |
24,156 |
|
- |
|
| Piacquad David |
SVP, Business Development |
• • – |
2018-05-03 |
4 |
D |
$169.43 |
$30,159 |
D/D |
(178) |
36,566 |
|
- |
|
| Hooper Anthony C |
EVP, Global Commercial Ops. |
• • – |
2018-05-03 |
4 |
D |
$169.43 |
$149,607 |
D/D |
(883) |
215,147 |
|
- |
|
2206 Records found
|
|
Page 23 of 89 |
|
|
0.67 (0.22%) 
